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The phosphoinositide family of phospholipids, deﬁned here as
PtdIns, PtdIns3P, PtdIns4P, PtdIns5P, PtdIns(3,4)P2, PtdIns(3,5)P2,
PtdIns(4,5)P2 and PtdIns(3,4,5)P3, play pivotal roles in organising
the location and activity of many different proteins acting on
biological membranes, including those involved in vesicle and
protein trafﬁcking through the endolysosomal system and receptor
signal transduction at the plasma membrane. Accurate measure-
ment of the cellular levels of these lipids, particularly the more
highly phosphorylated species, is hampered by their high polarity
and low cellular concentrations. Recently, much progress has been
made in using mass spectrometry to measure many different lipid
classes in parallel, an approach generally referred to as ‘lipidomics’.
Unfortunately, the acidic nature of highly phosphorylated phos-
phoinositides makes them difﬁcult to measure using these
methods, because they yield low levels of useful ions; this is
particularly the case with PtdIns(3,4,5)P3. We have solved some of
these problems by methylating the phosphate groups of these
lipids with TMS-diazomethane and describe a simple, integrated
approach to measuring PtdIns, PtdInsP, PtdInsP2 and PtdInsP3
classes of lipids, in parallel with other phospholipid species, in cell
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Inositol lipids, or phosphoinositides, comprise a distinct family of eight phospholipids, one or more
of which are found in all eukaryotic cells; these are PtdIns, PtdIns3P, PtdIns4P, PtdIns5P, PtdIns(3,4)P2,
PtdIns(3,5)P2, PtdIns(4,5)P2 and PtdIns(3,4,5)P3 (Fig. 1). They are interconverted by lipid kinases,
phosphatases and phospholipases which acutely regulate their levels in response to different envi-
ronmental cues. Several, perhaps all, of these lipids play major regulatory roles in cells by dictating the
localisation and function of proteins which act on the membrane inwhich they reside (Di Paolo and De
Camilli, 2006). In most examples studied to date, this involves the speciﬁc recognition of a phos-
phorylated inositol headgroup by a conserved protein domain, for example the binding of the
PtdIns(4,5)P2 or PtdIns(3,4,5)P3 headgroups by distinct families of pleckstrin homology (PH) domains
(Lemmon, 2008). Moreover, at least two of these lipids are involved in reactions which represent the
rate limiting steps in the generation of ‘second-messengers’ in response to activation of cell surfaceeukaryotic cells. The structure of PtdIns(3,4,5)P3 is shown with 18:0 (stearoyl,
he sn-1 and sn-2 positions, respectively, as an example of the major molecular
n of the references to colour in this ﬁgure legend, the reader is referred to the
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and Ins(1,4,5)P3 (Kadamur and Ross, 2013) and Class I phosphoinositide 3-kinase (PI3K)-catalysed
phosphorylation of PtdIns(4,5)P2 to PtdIns(3,4,5)P3 (Hawkins et al., 2006). DAG, Ins(1,4,5)P3 and
PtdIns(3,4,5)P3 are now well established to play major roles in coordinating cellular responses to a
huge range of different extracellular stimuli.
Despite major advances in our understanding of the cell biology and enzymology of this important
family of phospholipids, there are still surprisingly few studies which focus on the measurement of the
cellular levels of the lipids themselves. There are several reasons for this, but they mostly stem from
problems associated with the relatively low cellular levels of the more highly phosphorylated phos-
phoinositides (e.g. PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are usually present at less than 1% and 0.05%
respectively, of total cellular phospholipids in mammalian cells) (Stephens et al., 1993). Thus, the most
effective methods for measuring these lipids have usually used some form of enzyme-linked assay, or
radiolabelling with 32P-Pi or 3H-inositol precursors followed by HPLC of deacylated headgroups
(Guillou et al., 2007; Jones et al., 2013; Rusten and Stenmark, 2006; Sauer et al., 2009; Stephens et al.,
1991). Each of these methods requires specialised reagents, or is very laborious, and has limited
applicability across a range of sample formats (e.g. radiolabelling usually excludes the use of tissue
biopsies). The recent development of systematic approaches to measuring lipids in cells by mass
spectrometry, ‘lipidomics’, offers the promise of a new approach to this problem with high sensitivity,
high throughput and large dynamic range (Ivanova et al., 2009, Postle et al., 2007, Wenk et al., 2003).
However, despite some progress, this approach has been hampered by the low yield of ions generated
in the mass spectrometer derived from the more highly phosphorylated phosphoinositides, particu-
larly PtdInsP3 and PtdInsP2 (Milne et al., 2005; Pettitt et al., 2006; Vadnal and Parthasarathy, 1989).
We have recently solved this problem using chemical derivatisation of the acidic phosphate groups
on these lipids (Anderson et al., 2013, Clark et al., 2011). This method allows sensitive detection of all
phosphoinositide classes in parallel to other phospholipid families, but it does not yet allow resolution
of different regio-isomers (i.e. resolution of the 3-, 4-, 5- species of PtdInsP or (3,4)-, (3,5)- and (4,5)-
species of PtdInsP2). This means, for mammalian cells at least, that PtdInsP and PtdInsP2 estimates will
be dominated by the most abundant isomers of these classes, PtdIns4P and PtdIns(4,5)P2, respectively.
However, since PtdIns(3,4,5)P3 is the only PtdInsP3 isomer found in eukaryotic cells, this lipid is
measured without ambiguity. Moreover, phospholipid classes are known to represent families of
molecular species which differ in their fatty-acyl composition (Shindou et al., 2009, van Meer et al.,
2008). Thus, precise measurement of the masses of these species using mass spectrometry allows
for the ﬁrst time a systematic analysis of the fatty-acyl composition of PtdInsP2 and PtdInsP3.
We present here an overview of this methodology, explaining the rationale behind some of the
steps involved and our recent experience of applying it across a range of different cell and tissue types.
An integrated approach to measuring polyphosphoinositides
An overview of the methodology we have developed is shown in Fig. 2. Technical details of indi-
vidual steps can be found in (Anderson, Kielkowska, 2013; Clark, Anderson, 2011).
Extraction of lipids
We have found the most simple and effective method for quantitative extraction of all phosphoi-
nositides and most bulk phospholipids from cell and tissue samples uses an acidiﬁed, two phase
solvent system, ﬁrst described by Folch (Folch et al., 1957). The use of acidiﬁcation to suppress the
ionisation of polyphosphoinositide phosphate groups, together with the relatively polar organic phase
generated by this method, allows more effective partition of the highly polar phosphorylated phos-
phoinositides. Moreover, the acidiﬁed, methanol-containing organic phase was found to be an ideal
environment for the subsequent derivatisation reaction using TMS-diazomethane (see below).
Solid tissue (typically 0.1–0.5 mg wet weight, initially frozen in liquid nitrogen) or cell suspensions
(typically 105–106 cells) are initially extracted in a solvent mixture to yield a single phase containing
chloroform, methanol and acidiﬁed aqueous solution in the proportions 1.25:2.5:1.0 (v/v). Any internal
lipid standards (ISDs, see below) are added to this single phase at this point. We have often found bath
Fig. 2. A ﬂow diagram illustrating the overall procedure for extracting, derivatising and measuring phosphoinositides by mass
spectrometry.
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essential for effective lipid extraction. In cases where the solvent mixture will dissolve plastic con-
tainers (e.g. tissue culture dishes) we have found cell reactions can be terminated by the addition of ice-
cold 1 M HCl; the cells can then be scraped, transferred to polypropylene tubes and cell pellets
collected by centrifugation.
This single phase is then split by the addition of further chloroform, methanol and 0.1 MHCl to yield
ﬁnal proportions of chloroform, methanol and acidiﬁed aqueous solution of 8:4:3 (v/v). After thorough
mixing and brief centrifugation, this yields a two phase system in which the lipids of interest are
quantitatively extracted into the organic phase. After washing it with acidiﬁed aqueous phase, the
organic phase is carefully removed for derivatisation.
We have found this method is effective at quantitatively extracting phosphoinositides from a
wide range of plant, animal tissues and cells. However, in some cases, where the total lipid content
of the tissue is dominated by neutral lipids (like triglyceride in adipose tissue, or surfactant in
bronchiolar lavages), the sensitivity of PtdIns(3,4,5)P3 measurement can be substantially improved
by ﬁrst extracting and discarding the bulk neutral lipids using a non-acidiﬁed Folch phase parti-
tion, and then re-extracting the aqueous phase/protein interphase in the presence of additional
acid. However, this approach removes most of the less polar lipids, including PtdIns, and thus many
of the lipids with which measurements of PtdIns(3,4,5)P3 and PtdIns(4,5)P2 may wish to be
compared.
Derivatisation
The phosphate groups of phosphoinositides are reactedwith TMS-diazomethane for 10min at room
temperature, directly in the organic phase generated by the Folch extraction (see Fig. 3) (Clark,
Anderson, 2011). If the conditions of the reaction are adhered to, there is minimal methylation of
the free hydroxyls on the inositol ring and no modiﬁcation of the fatty acyl side chains. Excess TMS-
diazomethane is destroyed by the addition of acetic acid, and the derivatised lipids are puriﬁed
through two further rounds of a neutral Folch phase partition (acidiﬁcation is not required because the
phosphates are now methylated, and should be avoided to prevent phosphate migration/hydrolysis
during drying). The ﬁnal organic phase is then dried gently, before re-suspension in a solvent mixture
containing chloroform and methanol 8:2 (v/v).
Whilst the reaction with TMS-diazomethane was invented to radically improve the ionisation and
stability of ions generated from PtdInsP, PtdInsP2 and PtdInsP3 in the mass spectrometer, we have
Fig. 3. The reaction of PtdIns(3,4,5)P3 with TMS-diazomethane. TMS-diazomethane (B) reacts with hydroxyl groups of PtdInsP3(A)
to form unstable species (C). MeOH in this reaction acts as a reagent to remove TMS in the form of a methyl ether, as well as a source
of protons to facilitate formation of the reactive intermediate presented in structure (D). The methylation reaction is fast, giving rise
to the desired methylated PtdInsP3(E) and releasing nitrogen gas as a by-product. Methylation of only one hydroxyl group is shown
in the ﬁgure for simplicity.
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in parallel (see below).
Mass spectrometry
Samples of derivatised lipid extract are then partially puriﬁed and concentrated by HPLC through an
in-line C4 column before infusion into a triple quadrapole mass spectrometer in positive ion mode.
We have found the most useful fragmentation for phosphoinositides, yielding the highest quantity
of unambiguous ions, is cleavage at the diester phosphate bond, generating the loss of a neutral
headgroup and the detection of a positively charged DAGþ. We have found this type of fragmentation
can also be used for a range of other phospholipids, allowing useful parallel measurements (see Table
1). We routinely measure 20–30 individual lipid species from a single extract, typically 1–5 molecular
species from 5 to 10 different lipid classes.
The general work plan for a particular cell or tissue type is to ﬁrst run neural loss scans (NLSs) to
identify the range of DAG species that are associated with a particular headgroup; some typical NLSs for
PtdInsP2 derived from a mammalian tissue and a cultured cell line are shown in Fig. 4. This then allows
the identiﬁcation of the particular molecular species to target for accurate quantiﬁcation. Thus far, we
have found all phosphoinositide species derived from mammalian tissue are relatively molecularly ho-
mogenous for the 38:4 fatty-acyl species (Fig. 4; 18:0 in the sn-1 position and 20:4 in the sn-2 position)
(Anderson, Kielkowska, 2013; Lee et al., 2012), as ﬁrst noticed for PtdIns (Holub, 1986). However, cells
grown in culture, even primary cells grown for short periods of time, rapidly synthesise a more diverse
range of phosphoinositide molecular species; (Fig. 4), possibly because the serum used is relatively
deprived of 20:4 (arachidonate) or its metabolic precursor, 18:2 (linoleic acid) (Clark, Anderson, 2011;
Rouzer et al., 2006). There is still very little work describing molecular species of phosphoinositides
across different cells, tissues and organisms and therefore this is usually an important step in the analysis.
Once themajormolecular species of phosphoinositides present have been established, the next step is
to accurately quantify them by integrating Multiple Reaction Monitoring (MRM) chromatograms (see
Fig. 5). The integrated ion currents (‘peakareas’) aredirectly related toquantity, but eachmolecular species
and, inparticular, each lipid class is likely to have different efﬁciencies of ionisation and fragmentation and
thus theycannot generally be comparedwith eachotherwithout some formof cross-standardisation. This
is usually achieved by the inclusion of ISDs that are sufﬁciently chemically similar to the endogenous
Table 1
This table shows a list of phospholipid classes that we have successfully measured in lipid extracts derivatised with TMS
diazomethane.
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Fig. 4. Examples are presented for neutral loss scans (NLSs) measuring the DAGþ species generated by the loss of the derivatised
headgroup of PtdInsP2 (490.04 amu). The major peaks are annotated with the total fatty-acyl composition of the individual DAG
species (e.g. 38:4 is equivalent to 18:0/20:4, sn-1/sn-2); the trace has not been ‘de-isotoped’ and thus each molecular species is
represented by a series of þ1 masses related to the natural abundance of 13C. Note that mouse brain contains predominantly the
38:4 species, but mouse embryonic ﬁbroblasts (MEFs) have a wider diversity of molecular species, probably related to their culture
conditions.
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added at the point of initial solvent extraction, thiswill also include recoveries through the extraction and
derivatistion steps, as well as during HPLC and mass spectrometry). Unfortunately, for most phosphoi-
nositide species, the relevant ISDs are not commercially available and require a great deal of expertise to
synthesise chemically. The most obvious form of ISD is the precise equivalent to the endogenous species
except for the incorporation of heavy nuclei, which allow ‘mass distinction’. However, in case of
deuterated-C38:4 ISDs care should be taken as the molecules are unstable when stored in solution for
extended periods of time. The presence of double bonds in the structure makes these ISDs prone to
oxidationwhich becomes a problem, especiallywhenquantitativemeasurements are to be performed. As
an alternative, we have synthesised biologically irrelevant C16:0/C17:0 versions of these lipids (C17:0 is
rarely found in nature). We have found C33:0-PtdIns, -PtdInsP2 and -PtdInsP3 ISDs are stable, create ho-
mogenous solutions in chloroform/methanol mixtures and correct well for the recoveries of their
endogenous counterparts. Using ISDs, we have found that recoveries of endogenous lipids tail off
dramatically if toomuch tissue/cells are used (Fig. 6) and thus it is important to deﬁne aworking range of
sample size; typically we aim for 0.5 million cells and dilute solid tissue samples to give equivalently
concentrated lipid extracts.
This methodology can be used to measure phosphoinositides and other lipid species in tissue and
cell extracts with high levels of sensitivity and reproducibility, and a signiﬁcantly greater throughput
compared to most existing methods (40–60 samples can be routinely processed in a day). Impor-
tantly, this method represents a major advance in our ability to detect the very low levels of
PtdIns(3,4,5)P3 that are generated by cell surface receptor stimulation of Class I PI3Ks (see Fig. 7). This
opens up the possibility of directly assessing Class I PI3K activity in tissue biopsies derived from
pathophysiological contexts in which PI3Ks are deregulated, including human cancers and immune
cell dysfunctions.
Future prospects
One of the major limitations of the current methodology is the inability to resolve regioisomers of
polyphosphoinositides. Potential solutions to this problem could include improved HPLC separations
Fig. 5. A. A cartoon describing the fragmentation used to measure C38:4-PtdInsP3(Q1/Q3 1225.573/627.535), illustrating the prin-
ciple of the MRM transitions used. B. Examples of MRM traces used for measuring PtdInsP3 in extracts derived from control (left
panel) and EGF-stimulated (1 min, 2 ng/ml; right panel) MEFs, showing the excellent signal to noise ratios that can be achieved. Ion
current is plotted against HPLC elution time and integrated areas under the peaks are used to determine quantity of material. The
trace measuring endogenous C38:4-PtdInsP3(red) is overlaid with the trace measuring the C33:0-PtdInsP3 internal standard (blue);
the ratio between these two areas (response ratio) gives the relative quantities of endogenous material corrected for any losses
through the entire procedure.
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Fig. 6. An example showing how the recovery of endogenous PtdInsP2 and PtdInsP3 is related to the recovery of ISDs (d7-C38:4 PtdIns(4,5)P2 and C33:0 PtdIns(3,4,5)P3) from lipid extracts
prepared using increasing numbers of mouse neutrophils. There is clearly no advantage in using cell numbers beyond 1  105.
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Fig. 7. An example of measuring changes in the levels of C38:4-PtdInsP3 during EGF stimulation of MEFs (2 ng/ml EGF added at time
0).
A. Kielkowska et al. / Advances in Biological Regulation 54 (2014) 131–141140which resolve the isomers prior to infusion into the mass spectrometer, though this will be difﬁcult
using the intact lipid species and classical ‘reverse phase’ systems (since they will often be molecularly
diverse because of fatty-acyl heterogeneity and because the basis of the separation is largely hydro-
phobic). However, it may also be possible to devise new chemical approaches to the derivatisation of
the headgroup or to use a different fragmentation strategy to distinguish between the different
phosphorylated positions on the inositol headgroup. Another more tractable but nonetheless essential
advance is the chemical synthesis of a more comprehensive set of standards (ISDs) that can be used for
the robust and accurate quantiﬁcation of awider variety of phosphoinositides and other phospholipids.
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